Fate Therapeutics price target lowered to $4 from $5 at Baird
TipRanks
May. 14, 2025, 05:19 AM
Baird lowered the firm’s price target on Fate Therapeutics (FATE) to $4 from $5 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which met expectations.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
Disclaimer & DisclosureReport an Issue
- Fate Therapeutics price target lowered to $2 from $10 at Barclays
- Cautious Optimism for Fate Therapeutics Amid Promising Developments and Financial Stability
- Fate Therapeutics reports Q1 EPS (32c), consensus (38c)
- FATE Upcoming Earnings Report: What to Expect?
- Fate Therapeutics receives RMAT designation from FDA for FT819
